APOE and Alzheimer disease: ApoE-ε3 (Huang et al., 1995; DeMattos et al., 2001; Hopkins et al., 2002; Sen et al., 2012; Pedachenko et al., 2015; Mahan et al., 2022; Sepulveda-Falla et al., 2022; Mulgrave et al., 2023) and apoE-ε4 (Ayyubova, 2023; Chen et al., 2023; Hamza et al., 2023; Koutsodendris et al., 2023; Pires and Rego, 2023; Sun and Xie, 2023; Zhou et al., 2023) have been verified to be risk factors for AD.